Discuss your research with your peers
Would you like to react to this message? Create an account in a few clicks or log in to continue.
Discuss your research with your peers

Real time streaming news at http://www.myresearchnews.com

The website is brand new, you are helping us evolve. Please help us by contributing your thoughts on any topic, leave a comment, start a new discussion. Thanks a lot.

Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy

Discuss your research with your peers :: Molecular Biology :: Antisense Forum

Go down

Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy Empty Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy

Post  Jon Moulton Thu May 05, 2011 10:44 am

Sazani P, Van Ness KP, Weller DL, Poage DW, Palyada K, Shrewsbury SB. Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy. Int J Toxicol. 2011 May 3. [Epub ahead of print]
Jon Moulton
Jon Moulton

Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA

http://www.gene-tools.com

Back to top Go down

Back to top

- Similar topics
» Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
» Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
» Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for the Treatment of Duchenne Muscular Dystrophy (DMD): 168 Week Update on Six-Minute Walk Test (6MWT), Pulmonary Function Testing (PFT), and Safety
» Safety and pharmacokinetic profile of eteplirsen, SRP-4045, and SRP-4053, three phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with Duchenne muscular dystrophy (DMD)
» A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD)

Discuss your research with your peers :: Molecular Biology :: Antisense Forum

 
Permissions in this forum:
You cannot reply to topics in this forum